Menu
Recruiting NCT07230210

Smart Tech-Based Nutrition and Exercise for Sarcopenia Risk.

No phase Interventional Sarcopenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in.
Who it may be relevant to
Registry conditions: Sarcopenia. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effectiveness of Smart Technology Interventions Combining Nutrition and Exercise for Older Adults at Risk of Sarcopenia

Overview

Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. This randomized controlled trial (RCT) will evaluate a 12-week smart-technology-based program for 60 older adults at risk of sarcopenia. Intervention: Participants in the intervention group will receive a technology-assisted program delivered through a Line Bot system. The platform provides personalized exercise training videos, nutrition education, daily reminders, and a point-based logging system to support adherence and monitor engagement. The control group will receive standard clinic-based care. Purpose: The study aims to examine whether the smart technology intervention can improve muscle mass, physical performance, quality of life, and self-management ability among older adults at risk of sarcopenia. Expected Benefit: The digital intervention is anticipated to offer a more effective, accessible, and sustainable approach compared with standard care, providing practical support for preventing muscle decline in community-dwelling older adults

Detailed description

This randomized controlled trial (RCT) is designed as a 12-week intervention to evaluate the efficacy of a smart technology-assisted nutrition and exercise program for community-dwelling older adults (aged ≥ 65 years) at risk of sarcopenia. Participants (N = 60) will be randomly assigned to either the intervention group (n = 30) or the control group (n = 30). Data will be collected at baseline, week 8 (mid-intervention), and week 12 (post-intervention).

Intervention Group:

Participants will receive the 12-week program delivered through a dedicated Line Bot platform. Core components include:

Exercise Training: Three progressive exercise videos (resistance, aerobic, and balance training) designed to enhance muscle function.

Nutrition Education: One video focusing on adequate protein intake and dietary habits essential for muscle maintenance.

Smart Technology Features: The Line Bot functions as a personalized case management tool, offering daily reminders for exercise and protein intake, an interactive calculator for estimating daily protein consumption, and a digital logging system with motivational rewards to support adherence and self-management behaviors.

Control Group:

Participants will receive standard outpatient care and general health education pamphlets. They will not receive access to the Line Bot system, exercise videos, or personalized support.

Primary outcome data will be collected at week 12. Statistical analyses will include descriptive statistics and inferential methods, such as repeated measures analysis of variance (ANOVA), to examine the effectiveness of the intervention.

Interventions

  • Behavioral The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in
    The 12-week progressive exercise program (resistance, aerobic, and balance training) is uniquely delivered and monitored via a dedicated \*\*Line Bot platform\*\*. This differentiates it from traditional in-person or non-interactive video programs. The platform includes interactive features like daily reminders and a digital diary to enhance adherence and support participant self-management, aiming for five exercise sessions per week.

Primary outcome measures

  • Appendicular Skeletal Muscle Mass (ASM) by Bioelectrical Impedance Analysis (BIA) [Time frame: Baseline (Week 0), Week 8, and Final Assessment at Week 12.]

Eligibility criteria

Inclusion criteria

Score ≥ 11 on the SARC-CalF questionnaire, indicating risk of sarcopenia.

No evident functional impairment in the limbs and able to complete handgrip strength, walking speed, and muscle mass assessments.

Possesses basic reading, writing, and calculation abilities sufficient to understand study-related materials and complete informed consent and daily logs.

Owns a smartphone and has used it for at least one year, with basic operational ability (e.g., sending and receiving LINE messages, scanning QR codes).

Exclusion criteria

Self-reported functional impairment in any limb.

Requires assistance from a wheelchair, walker, or cane for ambulation.

Has an implanted cardiac pacemaker.

Currently participating in, or planning to participate in, other physical training courses or nutrition programs during the study period.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Taiwan · 1 center
  • BuddhistTCGH — Hualien City

Identifiers

NCT: NCT07230210 · IRB114-215-B · IRB114-215-B

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗